A LC–MS method to quantify tenofovir urinary concentrations in treated patients

摘要: Abstract Tenofovir disoproxil fumarate is a prodrug of tenofovir used in the treatment HIV and HBV infections: it most antiretroviral worldwide. nucleotidic reverse trascriptase inhibitor that showed excellent long-term efficacy tolerability. However renal bone complications (proximal tubulopathy, hypophosphatemia, decreased mineral density, reduced creatinine clearance) limit its use. toxicity has been suggested as consequence drug entrapment proximal tubular cells: measuring urinary concentrations may be proxy this event predictor side effects. No method currently available for quantifying matrix: then, aim work was to validate new LC–MS quantification tenofovir. Chromatographic separation achieved with gradient (acetonitrile water formic acid 0.05%) on an Atlantis 5 μm T3, 4.6 mm × 150 mm, reversed phase analytical column. Detection internal standard by electrospray ionization mass spectrometry positive ion mode. Calibration ranged from 391 100,000 ng/mL. The 391 ng/mL detection 195 ng/mL. Mean recovery were consistent stable, while matrix effect resulted low stable. tested 35 urine samples HIV-positive patients treated tenofovir-based HAARTs did not show any significant interference antiretrovirals or other concomitantly administered drugs. All observed real fitted calibration range, confirming capability use clinical routine. Whether confirmed ad hoc studies help managing